Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-07
2011-12-20
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S006900, C514S017700
Reexamination Certificate
active
08080523
ABSTRACT:
Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog. Such fluorophore tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells.
REFERENCES:
patent: 6077680 (2000-06-01), Kem et al.
patent: 6616944 (2003-09-01), Kissel et al.
patent: 6861405 (2005-03-01), Desir et al.
patent: 9823639 (1998-06-01), None
Pennington et al. Structural Stabilization and Minimization of the Potassium Channel Blocker, ShK Toxin. Peptides 2000, pp. 155-156.
Beeton et al. A Novel Fluorescent Toxin to Detect and Investigate Kv1.3 Channel Up-regulation in Chronically Activated T Lymphocytes. The Journal of Biological Chemistry. vol. 278, No. 11, Issue of Mar. 14, 2003. Published JBC Papers in Press,Jan. 2, 2003, pp. 9928-9937.
Hruby. Designing Peptide Receptor Agonists and Antagonists. Nature Reviews. Drug Discovery. Nov. 2002. vol. 1, pp. 847-858.
H.J.C. Berendsen. A Glimpse of the Holy Grail? Science (1998) 282, pp. 642-643.
Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976), pp. 1-7.
SIGMA. Designing Custom Peptides. http://www.sigma-genosys.com/peptide—design.asp (Accessed Dec. 16, 2004), 2 pages.
W.S. Messer, “Vasopressin and Oxytocin”, web document updated Apr. 3, 2000; http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm; 5 pages.
D.E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
Beeton et al. Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases. Molecular Pharmacology, 2005. vol. 67, No. 4, pp. 1369-1381.
Beeton, C et al., Selective blockage of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis experimental autoimmune encephalomyelitis, a model for multiple sclerosis, Proceedings of the National Academy of Sciences of USA, Nov. 20, 2001, pp. 13942-13947, vol. 98, No. 24, Washington, DC, US.
European Search Report in reference to PA 6031 PCT/EP, European Patent Office, Sep. 10, 2009, Munich.
George, C., K+ channels as targets for specific immunomodulation, Trends in Pharmacological Sciences, May 1, 2004, pp. 280-289, vol. 25, No. 5, Elsevier, Haywarth, GB.
Kalman, et al., ShK-Dap22, a Potent Kv1.3-specific Immunosuppressive Polypeptide, J. Biol Chem., 1998, vol. 273, No. 49, pp. 32697-32707.
Lanigan, M.D. et al., Designed Peptide Analogues of the Potassium Channel Blocker ShK Toxin; Biochemistry, 25; 40 (51):15528-37, Dec. 2001.
King D.S., et al, 1990, Int. J. Peptide Protein Res., 36, 255-266.
Pennington, et al., Int. J Peptide Protein Res., 46, 354-358, 1995.
Stewart, J.M., et al., Solid Phase Peptide Sythesis, 2nd Edition, Pierce Chemical Company, Rockford, III., 1984.
Wilken, J. et al., Chemical Protein Synthesis, Current Opin. Biotech., 9,412-426, 1998.
Albericio, F., Convergent Peptide Synthesis; in Methods in Enzymol. Ed G. Fields, Academic Press, New York, NY, pp. 313-335, Available online Dec. 8, 2003.
Beeton, C. et al., Targeting Effector Memory T Cells with a Selection Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases, Molecular Pharmacology, vol. 67, No. 4, 1369-, 2005.
Beeton, C. et al., A Novel Fluorescent Toxin to Detect and Investigate Kv1.3 Channel Up-Regulation in Chronically Activated T Lymhocytes, J. Biol. Chem., vol. 278, No. 11, 9928-9937, Mar. 2003.
Beeton Christine
Chandy George K.
Pennington Michael William
Buyan Robert D.
Cordero Garcia Marcela M
Stout, Uxa, Buyan & Mullins
The Regents of the University of California
LandOfFree
Analogs of ShK toxin and their uses in selective inhibition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analogs of ShK toxin and their uses in selective inhibition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogs of ShK toxin and their uses in selective inhibition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314299